Jeevan Scientific Technology Ltd
₹ 77.1
-7.42%
01 Jun
- close price
About
Incorporated in 1999, Jeevan Scientific Technology Ltd is an Independent Clinical Contract Research Organization which offers technology-driven clinical research solutions[1]
Key Points
- Market Cap ₹ 154 Cr.
- Current Price ₹ 77.1
- High / Low ₹ 93.9 / 32.8
- Stock P/E 134
- Book Value ₹ 36.1
- Dividend Yield 0.00 %
- ROCE 5.01 %
- ROE 1.89 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -7.80%
- Promoter holding is low: 30.2%
- Company has a low return on equity of -0.01% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.39 | 18.21 | 20.39 | 26.13 | 23.94 | 46.90 | 67.79 | 36.18 | 39.65 | 46.84 | 61.54 | |
| 15.59 | 15.01 | 16.96 | 20.27 | 30.02 | 29.41 | 51.02 | 34.82 | 35.01 | 39.37 | 51.74 | |
| Operating Profit | 1.80 | 3.20 | 3.43 | 5.86 | -6.08 | 17.49 | 16.77 | 1.36 | 4.64 | 7.47 | 9.80 |
| OPM % | 10.35% | 17.57% | 16.82% | 22.43% | -25.40% | 37.29% | 24.74% | 3.76% | 11.70% | 15.95% | 15.92% |
| 0.37 | 0.58 | 0.92 | 1.00 | 2.50 | 2.39 | 5.91 | 1.07 | 0.67 | 0.65 | 0.97 | |
| Interest | 1.28 | 1.54 | 1.87 | 2.36 | 3.04 | 2.26 | 0.96 | 1.04 | 0.98 | 1.82 | 2.04 |
| Depreciation | 0.68 | 1.23 | 2.12 | 3.13 | 3.92 | 3.97 | 3.69 | 5.07 | 5.93 | 6.25 | 6.64 |
| Profit before tax | 0.21 | 1.01 | 0.36 | 1.37 | -10.54 | 13.65 | 18.03 | -3.68 | -1.60 | 0.05 | 2.09 |
| Tax % | 104.76% | 10.89% | 69.44% | 18.25% | -18.60% | 13.99% | 33.78% | -16.58% | -17.50% | -20.00% | 50.72% |
| -0.01 | 0.90 | 0.11 | 1.11 | -8.59 | 11.74 | 11.94 | -3.07 | -1.33 | 0.05 | 1.03 | |
| EPS in Rs | -0.02 | 0.97 | 0.10 | 0.73 | -5.61 | 7.67 | 7.80 | -1.97 | -0.84 | 0.08 | 0.58 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6.52% | 15.38% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 6% |
| 3 Years: | 19% |
| TTM: | 31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 45% |
| 5 Years: | -37% |
| 3 Years: | 33% |
| TTM: | 721% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | -4% |
| 3 Years: | 19% |
| 1 Year: | 86% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 0% |
| Last Year: | 2% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.04 | 9.28 | 11.46 | 15.30 | 15.30 | 15.30 | 15.30 | 15.48 | 15.48 | 15.83 | 19.92 |
| Reserves | -2.27 | 7.60 | 10.55 | 16.53 | 7.92 | 19.72 | 35.28 | 32.71 | 32.95 | 34.11 | 52.02 |
| 11.08 | 8.45 | 18.78 | 18.15 | 17.95 | 10.34 | 12.55 | 10.10 | 13.41 | 20.58 | 21.28 | |
| 5.56 | 5.56 | 8.59 | 11.32 | 12.70 | 20.62 | 14.75 | 7.63 | 6.03 | 7.77 | 13.37 | |
| Total Liabilities | 20.41 | 30.89 | 49.38 | 61.30 | 53.87 | 65.98 | 77.88 | 65.92 | 67.87 | 78.29 | 106.59 |
| 8.67 | 16.35 | 28.17 | 32.59 | 30.54 | 27.38 | 19.07 | 24.97 | 26.66 | 34.55 | 36.08 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.90 | 2.81 | 4.71 | 4.71 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.98 |
| 11.74 | 14.54 | 21.21 | 28.71 | 23.33 | 38.60 | 58.81 | 39.05 | 38.40 | 39.03 | 62.82 | |
| Total Assets | 20.41 | 30.89 | 49.38 | 61.30 | 53.87 | 65.98 | 77.88 | 65.92 | 67.87 | 78.29 | 106.59 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.55 | -5.62 | 5.65 | 4.04 | -0.01 | 4.95 | 19.56 | -6.41 | 2.89 | 10.07 | ||
| -3.63 | -8.90 | -14.35 | -7.87 | -1.90 | -0.80 | -1.20 | -6.93 | -11.53 | -15.62 | ||
| 0.23 | 14.57 | 9.86 | 6.08 | 0.44 | -0.13 | 5.67 | -9.54 | 2.35 | 5.24 | ||
| Net Cash Flow | 0.15 | 0.05 | 1.17 | 2.25 | -1.47 | 4.02 | 24.03 | -22.88 | -6.29 | -0.30 | |
| Free Cash Flow | -0.08 | -14.52 | -8.70 | -3.83 | -1.91 | 4.15 | 17.33 | -14.57 | -9.14 | -5.96 | |
| CFO/OP | 197% | -176% | 165% | 69% | 32% | 39% | 153% | -269% | 101% | 135% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 151.96 | 227.10 | 291.79 | 205.20 | 104.29 | 112.46 | 40.97 | 117.83 | 113.14 | 124.21 | 122.71 |
| Inventory Days | 72.11 | 105.50 | 104.15 | 155.61 | 226.63 | ||||||
| Days Payable | 98.78 | 322.56 | 205.43 | 305.45 | 458.49 | ||||||
| Cash Conversion Cycle | 151.96 | 227.10 | 291.79 | 205.20 | 104.29 | 112.46 | 14.30 | -99.23 | 11.85 | -25.63 | -109.15 |
| Working Capital Days | 52.05 | 90.60 | 35.44 | -3.07 | -100.78 | 37.36 | 10.18 | 110.67 | 137.35 | 128.19 | 121.41 |
| ROCE % | 12.69% | 6.75% | 8.22% | -16.39% | 36.77% | 27.58% | -4.34% | -1.03% | 2.80% | 5.01% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioanalytical Instrument - LC-MS/MS Units Number of Units ・Standalone data |
|
||||||||||
| Annual Study Execution Capacity (at peak) Number of Studies ・Standalone data |
|||||||||||
| Clinical Bed Capacity Beds ・Standalone data |
|||||||||||
| Total Employee Headcount Number of Employees |
|||||||||||
| Cumulative Successful Regulatory Inspections Number of Inspections ・Standalone data |
|||||||||||
| Total Clinical Studies Completed to Date Number of Studies ・Standalone data |
|||||||||||
| Bioanalytical Methods Developed Number of Methods ・Standalone data |
|||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Statement Of Deviation Or Variation Of Funds
29 May - No deviation in use of ₹3,074 lakh preferential allotment proceeds for FY ended March 31, 2026.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Annual secretarial compliance report for FY2026 notes Rs 2,360 fine for Stakeholders Committee non-compliance.
-
Announcement under Regulation 30 (LODR)-Change in Management
29 May - Board approved FY26 audited results, unmodified audit opinion, appointed internal auditor, granted 4.8 lakh options, allotted 1.6125 lakh shares.
- Audited Financial Results For The Quarter And Year Ended 31.03.2026 29 May
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 29.05.2026
29 May - Board approved FY26 audited results, unmodified opinion, 4.8 lakh ESOPs, and allotted 1.61 lakh shares.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Services Offered:[1][2]
a) Clinical Trial Services:
Patient PK trials, Pharmacodynamic endpoint studies, Early & late phase clinical trials, Post-marketing surveillance studies, Investigator initiated and real-world evidence studies,
Clinical Trials Support for Complex Generics
& Biosimilars
b) Bioavailability & Bioequivalence Services:
MD/MV and subject sample analysis, Statistical Analysis and Data Management, SAS and Win Nonlin, CDISC, Healthy and Patient based BA/BE studies Food effect, Age Effect, Gender effect studies, Studies in both male and female subjects (Pre and Postmenopausal women), PK/PD endpoint studies, SAD and MAD studies, etc.
c) Pharmacovigilance Services:
Data migration, Database management, Literature search services, regulatory inspection /audit support, etc.